Raymond James Financial Inc. Buys New Stake in Stevanato Group S.p.A. (NYSE:STVN)

Raymond James Financial Inc. purchased a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 264,084 shares of the company’s stock, valued at approximately $5,754,000. Raymond James Financial Inc. owned 0.09% of Stevanato Group as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in STVN. TimesSquare Capital Management LLC raised its stake in shares of Stevanato Group by 114.6% during the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock worth $71,657,000 after buying an additional 1,756,100 shares during the period. Jennison Associates LLC purchased a new stake in Stevanato Group in the 4th quarter worth $20,239,000. Mutual of America Capital Management LLC acquired a new position in Stevanato Group during the fourth quarter worth $13,848,000. New York State Common Retirement Fund purchased a new position in Stevanato Group during the fourth quarter valued at $8,879,000. Finally, Conestoga Capital Advisors LLC grew its position in shares of Stevanato Group by 5.3% in the fourth quarter. Conestoga Capital Advisors LLC now owns 8,082,996 shares of the company’s stock valued at $176,128,000 after purchasing an additional 407,086 shares during the period.

Analysts Set New Price Targets

STVN has been the subject of several research analyst reports. Bank of America upped their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Wolfe Research began coverage on Stevanato Group in a report on Friday, December 13th. They set an “outperform” rating and a $28.00 target price for the company. UBS Group lowered their price target on Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research note on Friday, March 7th. Morgan Stanley reissued an “equal weight” rating and issued a $23.00 price objective (down from $24.00) on shares of Stevanato Group in a research note on Tuesday, December 3rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Stevanato Group in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of €27.75 ($29.84).

Stevanato Group Trading Down 0.8 %

Shares of STVN stock opened at €22.34 ($24.02) on Tuesday. Stevanato Group S.p.A. has a twelve month low of €16.56 ($17.81) and a twelve month high of €33.49 ($36.01). The stock has a market cap of $6.77 billion, a price-to-earnings ratio of 47.53, a PEG ratio of 7.18 and a beta of 0.60. The company’s 50-day moving average price is €21.04 and its 200-day moving average price is €20.59. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22.

Stevanato Group (NYSE:STVN) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of €0.20 ($0.22). Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The company had revenue of €352.68 million during the quarter, compared to analysts’ expectations of €346.26 million. As a group, equities analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.